Grunze H, Erfurth A, Amann B, Normann C, Walden J
Psychiatrische Universitätsklinik der LMU München.
Fortschr Neurol Psychiatr. 1999 Jun;67(6):256-60. doi: 10.1055/s-2007-994974.
We present the case of a 60-year old bipolar-I-patient showing a rapid antimanic response to gabapentin after having been non-responsive to lithium and perazine. This case encouraged us to further evaluate the antimanic potency of gabapentin in an open label trial. 20 patients with acute mania were treated for up to 21 days with gabapentin in a dose range from 1200 to 4800 mg/day. Ten patients were treated with gabapentin as add-on medication and ten patients were treated with a high dose of gabapentin alone. The BRMAS score declined significantly in patients with moderate mania, whereas gabapentin alone was not efficacious in patients with very severe mania. Keeping in mind the limitations of an open study, it can still be said that gabapentin as add-on medication with other effective mood stabilizers appears to be safe and efficacious in the treatment of moderate mania.
我们报告了一例60岁的双相I型患者，该患者在对锂盐和奋乃静无反应后，对加巴喷丁表现出快速的抗躁狂反应。该病例促使我们在一项开放标签试验中进一步评估加巴喷丁的抗躁狂效力。20例急性躁狂患者接受加巴喷丁治疗长达21天，剂量范围为1200至4800毫克/天。10例患者将加巴喷丁作为附加药物治疗，10例患者单独使用高剂量加巴喷丁治疗。中度躁狂患者的BRMAS评分显著下降，而单独使用加巴喷丁对极重度躁狂患者无效。考虑到开放研究的局限性，仍可以说加巴喷丁作为与其他有效情绪稳定剂的附加药物，在治疗中度躁狂方面似乎是安全有效的。
